Avalon Pharmaceuticals to Present at Bear Stearns 20th Annual Healthcare Conference
30 August 2007 - 9:00PM
PR Newswire (US)
GERMANTOWN, Md., Aug. 30 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (NASDAQ:AVRX), today announced that Kenneth
C. Carter, Ph.D., President and CEO, is scheduled to provide an
update on the Company at the Bear Stearns 20th Annual Healthcare
Conference. The conference will be held at the Grand Hyatt Hotel in
New York City on Sept. 10-11, 2007. Dr. Carter is scheduled to
present on Tuesday, Sept. 11th, at 9:30 a.m. EDT. The presentation
will be available live via webcast and can be accessed through the
investor page of Avalon Pharmaceuticals' website at:
http://www.avalonrx.com/. An archive of the presentation will be
available for 90 days following the conference. About Avalon
Pharmaceuticals Avalon is a biopharmaceutical company focused on
the discovery, development and commercialization of first-in-class
cancer therapeutics. Avalon's lead product candidate, AVN944, an
IMPDH inhibitor, is in Phase II clinical development. Avalon also
has preclinical programs to develop inhibitors of the Beta-catenin
and Aurora/Centrosome pathways, discovery programs for inhibitors
of the survivin and Myc pathways and partnerships with Merck,
MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx(R) is the
company's proprietary platform which is based on large-scale
biomarker identification and monitoring, used to discover and
develop therapeutics for pathways that have historically been
characterized as "undruggable." Avalon is headquartered in
Germantown, Md. Contacts: Avalon Pharmaceuticals, Inc. Russo
Partners, LLC C. Eric Winzer Wendy Lau (Media) Executive Vice
President & Tel: (212) 845-4272 Chief Financial Officer Tel:
(301) 556-9900 The Trout Group LLC Fax: (301) 556-9910 Chad Rubin
(Investors) Email: Tel: (646) 378-2947 DATASOURCE: Avalon
Pharmaceuticals, Inc. CONTACT: C. Eric Winzer, Executive Vice
President & Chief Financial Officer of Avalon Pharmaceuticals,
Inc., +1-301-556-9900, Fax: +1-301-556-9910, ; or Media, Wendy Lau
of Russo Partners, LLC, +1-212-845-4272; or Investors, Chad Rubin
of The Trout Group LLC, +1-646-378-2947, both for Avalon
Pharmaceuticals, Inc. Web site: http://www.avalonrx.com/
Copyright
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Avalon Pharmaceuticals (MM) (NASDAQ): 0 recent articles
More Avalon Pharmaceuticals (MM) News Articles